This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A PRELIMINARY REPORT

WINFIELD L. BUTSCH, M.D.; JOHN D. STEWART, M.D.

Arch Surg. 1942;45(4):551-553.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The practical value of the use of an agent to prolong the clotting time of the blood in the prophylaxis and treatment of thromboembolic disease has been amply demonstrated. Administration of an anticoagulant, such as heparin, has been found to be safe for operative patients immediately after¹ or even before operation.² Heparin has reduced the expected occurrence of thrombosis and embolism in operative patients.¹ It has served well in the management of patients with nonfatal pulmonary embolism.¹ It has materially reduced the morbidity rate associated with thrombophlebitis.¹ The principles of its use have been established. But two factors, the expense and the comparative difficulty of administration, have tempered the enthusiasm for heparin and prevented its acceptance as a measure available to all. For this reason the results of the use of another anticoagulant, dicoumarin compound, 3,3'-methylenebis-4-hydroxycoumarin,³ have been studied in order to explore its . . . [Full Text PDF of this Article]

Author Affiliations
BUFFALO

From the Department of Surgery, University of Buffalo School of Medicine, and the Surgical Service of the Edward J. Meyer Memorial Hospital.

Footnotes
3,3'-methylenebis-4-hydroxycoumarin.

The dicoumarin compound used in this study was furnished by the Abbott Laboratories.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?